Wortmannin exhibits anticancer activity in oral cancer cell line by targeting PI3K, AKT and mTOR pathway.

Key Points

• The research aims to explore wortmannin's anticancer properties through targeted molecular pathways in oral cancer.
• Implemented an in-silico strategy to assess wortmannin's effects.
• Identified key molecular targets including PI3K, AKT, and mTOR.
• Designed further assays to validate findings in lab settings.
• Wortmannin showed promising anticancer activity against oral cancer cell lines.
• Targeting PI3K, AKT, and mTOR pathways indicated a potential therapeutic route.
• Further validation through in-vivo studies is necessary for clinical application.